MA50128B1 - Anticorps monoclonaux liants le recepteur trbv9 des lymphocytes t et procédés de leur utilisation - Google Patents

Anticorps monoclonaux liants le recepteur trbv9 des lymphocytes t et procédés de leur utilisation

Info

Publication number
MA50128B1
MA50128B1 MA50128A MA50128A MA50128B1 MA 50128 B1 MA50128 B1 MA 50128B1 MA 50128 A MA50128 A MA 50128A MA 50128 A MA50128 A MA 50128A MA 50128 B1 MA50128 B1 MA 50128B1
Authority
MA
Morocco
Prior art keywords
trbv9
monoclonal antibodies
antibody
receptor
family
Prior art date
Application number
MA50128A
Other languages
English (en)
Other versions
MA50128A1 (fr
Inventor
?Lga Vladimirovna Britanova
Mark Aleksandrovic Izraelson
Sergey Anatolievich Lukyanov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA50128A1 publication Critical patent/MA50128A1/fr
Publication of MA50128B1 publication Critical patent/MA50128B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des anticorps monoclonaux qui se lient spécifiquement à la famille trbv9 ? De récepteurs t de l'humain. L'invention concerne également un acide nucléique codant pour cet anticorps ou son fragment de liaison d'antigènes, un vecteur d'expression, un procédé de production d'anticorps et l'utilisation de l'anticorps pour traiter les maladies ou troubles liés à la famille des récepteurs t de l'humain. L'invention vise à créer des anticorps qui peuvent être utilisés pour éliminer les cellules t portant le récepteur de cellules de la famille t trbv9, notamment pour la thérapie ac, de maladie coeliaque et de maladies malignes du sang dans la pathogénèse desquelles est impliqué récepteur de cellules de la famille t trbv9.
MA50128A 2017-12-25 2018-12-25 Anticorps monoclonaux liants le recepteur trbv9 des lymphocytes t et procédés de leur utilisation MA50128B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2017145662A RU2694412C9 (ru) 2017-12-25 2017-12-25 Моноклональные антитела и способы их применения
PCT/RU2018/050168 WO2019132738A1 (fr) 2017-12-25 2018-12-25 Anticorps monoclonaux et procédés de leur utilisation

Publications (2)

Publication Number Publication Date
MA50128A1 MA50128A1 (fr) 2021-07-29
MA50128B1 true MA50128B1 (fr) 2022-09-30

Family

ID=67002533

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50128A MA50128B1 (fr) 2017-12-25 2018-12-25 Anticorps monoclonaux liants le recepteur trbv9 des lymphocytes t et procédés de leur utilisation

Country Status (20)

Country Link
US (2) US11597767B2 (fr)
EP (1) EP3733705A4 (fr)
JP (1) JP7339948B2 (fr)
KR (1) KR20200103774A (fr)
CN (1) CN111801354A (fr)
AU (1) AU2018398341A1 (fr)
BR (1) BR112020012959A2 (fr)
CA (1) CA3086849A1 (fr)
CL (1) CL2020001726A1 (fr)
CR (1) CR20200324A (fr)
EA (1) EA202091569A1 (fr)
EC (1) ECSP20039728A (fr)
JO (1) JOP20200161A1 (fr)
MA (1) MA50128B1 (fr)
MX (1) MX2020006736A (fr)
NI (1) NI202000051A (fr)
PH (1) PH12020551012A1 (fr)
RU (1) RU2694412C9 (fr)
WO (1) WO2019132738A1 (fr)
ZA (1) ZA202003858B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3818083A2 (fr) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Molécules d'anticorps anti-tcr et leurs utilisations
RU2711871C1 (ru) 2018-12-25 2020-01-23 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Моноклональные антитела, которые специфически связываются с участком бета цепи семейства TRBV-9 Т-клеточного рецептора человека, и способы их применения
RU2712251C1 (ru) * 2018-12-25 2020-01-27 Федеральное государственное автономное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
WO2024039268A1 (fr) * 2022-08-18 2024-02-22 Акционерное общество "БИОКАД" Procédé de traitement de maladie induite par des lymphocytes t

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223426A (en) 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5766947A (en) 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
RU2014144463A (ru) * 2009-06-25 2015-06-20 Фред Хатчинсон Кансэр Рисёч Сентер Способ измерения адаптивного иммунитета
EP3202784A1 (fr) * 2016-02-08 2017-08-09 Polybiocept AB Séquences de récepteurs de lymphocytes t pour une immunothérapie active
JP6952225B2 (ja) * 2016-03-18 2021-10-20 北海道公立大学法人 札幌医科大学 Ｔ細胞レセプターとその利用
EP3472208B9 (fr) 2016-06-17 2023-10-04 Medigene Immunotherapies GmbH Récepteurs de lymphocytes t et leurs utilisations

Also Published As

Publication number Publication date
CA3086849A1 (fr) 2019-07-04
RU2694412C9 (ru) 2019-09-18
RU2694412C2 (ru) 2019-07-12
EP3733705A1 (fr) 2020-11-04
RU2017145662A3 (fr) 2019-06-25
ZA202003858B (en) 2021-07-28
BR112020012959A2 (pt) 2020-12-01
AU2018398341A1 (en) 2020-07-30
WO2019132738A1 (fr) 2019-07-04
US11597767B2 (en) 2023-03-07
US20200332003A1 (en) 2020-10-22
JOP20200161A1 (ar) 2022-10-30
CL2020001726A1 (es) 2021-03-05
JP2021509274A (ja) 2021-03-25
KR20200103774A (ko) 2020-09-02
PH12020551012A1 (en) 2021-09-01
US20230357396A1 (en) 2023-11-09
ECSP20039728A (es) 2020-08-31
JP7339948B2 (ja) 2023-09-06
NI202000051A (es) 2021-12-16
CR20200324A (es) 2020-10-08
EA202091569A1 (ru) 2021-02-11
MA50128A1 (fr) 2021-07-29
MX2020006736A (es) 2020-08-24
CN111801354A (zh) 2020-10-20
RU2017145662A (ru) 2019-06-25
EP3733705A4 (fr) 2021-09-01

Similar Documents

Publication Publication Date Title
MA50128B1 (fr) Anticorps monoclonaux liants le recepteur trbv9 des lymphocytes t et procédés de leur utilisation
Grönwall et al. Autoreactivity to malondialdehyde-modifications in rheumatoid arthritis is linked to disease activity and synovial pathogenesis
Li et al. Autoantibodies from single circulating plasmablasts react with citrullinated antigens and Porphyromonas gingivalis in rheumatoid arthritis
Lampe et al. Polyclonal B cell activation by the Eta-1 cytokine and the development of systemic autoimmune disease.
MA44547A1 (fr) Anticorps anti-pd-1,procédé de leur production et de leur utilisation
JP2724625B2 (ja) ＩｇＥ産出性Ｂリンパ球上の独特な抗原決定基
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA31246B1 (fr) Anticorps antagoniste d'ox40, et leur utilisation dans le traitement de maladies inflammatoires et auto-immunes
JP2018508462A5 (fr)
MA53688A1 (fr) Anticorps monoclonaux qui se lient spécifiquement à trbv-9 de l'humain
MA31225B1 (fr) Anticorps neutralisants des cytomegalovirus humains et leur utilisation
TWI678376B (zh) 經改良之Ａβ原纖維結合抗體
WO2018115225A1 (fr) Anticorps monoclonaux anti-alpha-synucléine pour prévenir l'agrégation de la protéine tau
MA31634B1 (fr) Anticorps humains en cd20 humain et leur procede d'utilisation
JP7331168B2 (ja) 多発性骨髄腫におけるｍタンパク質反応の臨床評価
CN111518206B (zh) 人源化抗Aβ单克隆抗体及其应用
CR20210492A (es) ANTICUERPOS CONTRA AMILOIDES-ß CON PIROGLUTAMATO Y USOS DE ESTOS
MA53689B1 (fr) Anticorps humanisés contre un fragment bêta d'une chaîne de la famille 9 du récepteur cellulaire trbv-9 de l'humain et méthodes de leur application
MA44917A1 (fr) Anticorps ou son fragment de liaison d’antigènes apte a se lier au récepteur d'interleukine-6 de l'humain.
CN113508131B (zh) 人源化抗Aβ单克隆抗体及其应用
US20150126714A1 (en) Method for producing complete human neutralizing antibody for high mobility group box 1 (hmgb1) and the use to treat or inhibit hmgb1-associated neuromyelitis
JPH0292298A (ja) Ｈｉｖ構成蛋白に対するモノクローナル抗体
MA35580B1 (fr) Composition pharmaceutique
MA37998B2 (fr) Anticorps anti-cd3, molécules de liaison à un antigène bispécifiques qui se lient à cd3 et cd20, et leurs utilisations